ALGS Key Statistics, Chart & Performance
The current stock price of ALGS is 9.86 USD. In the past month the price increased by 14.52%. In the past year, price decreased by -61.35%.
ALGS Latest News, Press Relases and Analysis
ALGS Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.09 | 402.18B | ||
| AMGN | AMGEN INC | 15.76 | 185.50B | ||
| GILD | GILEAD SCIENCES INC | 15.57 | 158.22B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.89 | 110.80B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.43 | 83.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 872.78 | 58.35B | ||
| INSM | INSMED INC | N/A | 43.23B | ||
| NTRA | NATERA INC | N/A | 32.54B | ||
| BIIB | BIOGEN INC | 10.87 | 26.67B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.51 | 22.09B | ||
| INCY | INCYTE CORP | 16.46 | 20.63B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.21B |
Related stock screener links
About ALGS
Company Profile
Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the provision of therapeutics for chronic liver diseases and viral infections. The company is headquartered in South San Francisco, California and currently employs 70 full-time employees. The company went IPO on 2020-10-16. Its pipeline of drug candidates includes ALG-000184 for chronic HBV infection, ALG-055009 for MASH, ALG-097558 for coronavirus infections, and a portfolio of preclinical programs. ALG-000184 is a potential Capsid Assembly Modulator (CAM-E) for chronic HBV infection with enhanced pharmacologic properties. In the area of chronic HBV infection, its advanced drug candidate, ALG-000184, helps in disrupting the HBV lifecycle with viral suppression as well as reductions in viral antigens. Its ALG-055009 is an oral, small-molecule thyroid receptor beta agonist (THR-β) for the treatment of MASH.
Company Info
ALIGOS THERAPEUTICS INC
One Corporate Dr., 2Nd Floor, 2nd Floor
South San Francisco CALIFORNIA 94080 US
CEO: Lawrence M. Blatt
Employees: 70
Phone: 18004666059
ALIGOS THERAPEUTICS INC / ALGS FAQ
Can you describe the business of ALIGOS THERAPEUTICS INC?
Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the provision of therapeutics for chronic liver diseases and viral infections. The company is headquartered in South San Francisco, California and currently employs 70 full-time employees. The company went IPO on 2020-10-16. Its pipeline of drug candidates includes ALG-000184 for chronic HBV infection, ALG-055009 for MASH, ALG-097558 for coronavirus infections, and a portfolio of preclinical programs. ALG-000184 is a potential Capsid Assembly Modulator (CAM-E) for chronic HBV infection with enhanced pharmacologic properties. In the area of chronic HBV infection, its advanced drug candidate, ALG-000184, helps in disrupting the HBV lifecycle with viral suppression as well as reductions in viral antigens. Its ALG-055009 is an oral, small-molecule thyroid receptor beta agonist (THR-β) for the treatment of MASH.
Can you provide the latest stock price for ALIGOS THERAPEUTICS INC?
The current stock price of ALGS is 9.86 USD. The price increased by 2.07% in the last trading session.
Does ALIGOS THERAPEUTICS INC pay dividends?
ALGS does not pay a dividend.
How is the ChartMill rating for ALIGOS THERAPEUTICS INC?
ALGS has a ChartMill Technical rating of 5 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the GICS sector and industry of ALGS stock?
ALIGOS THERAPEUTICS INC (ALGS) operates in the Health Care sector and the Biotechnology industry.
Should I buy ALGS stock?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on ALGS.
What is the market capitalization of ALGS stock?
ALIGOS THERAPEUTICS INC (ALGS) has a market capitalization of 60.64M USD. This makes ALGS a Micro Cap stock.
ALGS Technical Analysis
ChartMill assigns a technical rating of 5 / 10 to ALGS. When comparing the yearly performance of all stocks, ALGS is a bad performer in the overall market: 90.71% of all stocks are doing better.
ALGS Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to ALGS. ALGS scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
ALGS Financial Highlights
Over the last trailing twelve months ALGS reported a non-GAAP Earnings per Share(EPS) of -10.08. The EPS increased by 24.04% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -78.77% | ||
| ROE | -120.37% | ||
| Debt/Equity | 0 |
ALGS Forecast & Estimates
10 analysts have analysed ALGS and the average price target is 81.86 USD. This implies a price increase of 730.17% is expected in the next year compared to the current price of 9.86.
For the next year, analysts expect an EPS growth of 28.04% and a revenue growth -29.69% for ALGS